Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1995;92:3568-3573

This Article
Right arrow Full Text
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruzicka, M.
Right arrow Articles by Leenen, F. H.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruzicka, M.
Right arrow Articles by Leenen, F. H.H.

(Circulation. 1995;92:3568-3573.)
© 1995 American Heart Association, Inc.


Articles

Effects of ACE Inhibitors on Circulating Versus Cardiac Angiotensin II in Volume OverloadInduced Cardiac Hypertrophy in Rats

Marcel Ruzicka, MD, PhD; Vaclav Skarda, PhD; Frans H.H. Leenen, MD, PhD, FRCP(C)

From the Hypertension Unit, University of Ottawa Heart Institute, Ontario, Canada.

Correspondence to Dr Frans H.H. Leenen, Hypertension Unit Room H360, University of Ottawa Heart Institute, 1053 Carling Ave, Ottawa, Ontario, K1Y 4E9 Canada.

Background Cardiac volume overload by an aortocaval shunt increases left ventricular end-diastolic pressure (LVEDP) and plasma and cardiac renin activity and results in LV hypertrophy. To a similar extent, the angiotensin-converting enzyme (ACE) inhibitors enalapril and quinapril prevent the increase in LVEDP. However, only quinapril attenuates the development of LV hypertrophy. We hypothesize that a low affinity of enalapril for cardiac ACE results in continuing generation of cardiac angiotensin II and thus hypertrophic growth of cardiomyocytes.

Methods and Results In the present study, we assessed plasma and cardiac angiotensins I and II 1 and 7 days after aortocaval shunt and the effects of enalapril and quinapril started 3 days before surgery on plasma and cardiac angiotensin I and II at the same time points. Aortocaval shunt increased plasma angiotensin II at 1 day by 180%, but only a small increase (by 40%) persisted at 7 days. Aortocaval shunt increased LV angiotensin II by 100% and 65% at 1 and 7 days, respectively. Both blockers similarly prevented the increase in plasma angiotensin II by aortocaval shunt at both time points. In contrast, only quinapril prevented the rise in LV angiotensin II induced by shunt at 1 and 7 days.

Conclusions Aortocaval shunt increases LVEDP and plasma and cardiac angiotensin II and results in LV hypertrophy. Only prevention of the increase in LVEDP and in plasma and cardiac angiotensin II attenuates the development of LV hypertrophy, consistent with the concept that angiotensin II is involved in the development of cardiac hypertrophy by aortocaval shunt by both hemodynamic and cardiac trophic effects. This study is the first to show that differences in affinity for cardiac ACE may determine the effect of ACE inhibitors on cardiac angiotensin II and therefore cardiac hypertrophy.


Key Words: angiotensin • enzymes • cardiac volume • hypertrophy




This article has been cited by other articles:


Home page
Journal of Renin-Angiotensin-Aldosterone SystemHome page
T. J Vittorio, K. Ahuja, M. Kasper, H. Turalic, C.-H. Tseng, U. P Jorde, and C. Gor
Comparison of high- versus low-tissue affinity ACE-inhibitor treatment on circulating aldosterone levels in patients with chronic heart failure
Journal of Renin-Angiotensin-Aldosterone System, December 1, 2007; 8(4): 200 - 204.
[Abstract] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
S. A. Saha, J. Molnar, and R. R. Arora
Tissue ACE Inhibitors for Secondary Prevention of Cardiovascular Disease in Patients With Preserved Left Ventricular Function: A Pooled Meta-analysis of Randomized Placebo-controlled Trials
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2007; 12(3): 192 - 204.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
W. J. Cheung, M.-A. H. Kent, E. El-Shahat, H. Wang, J. Tan, R. White, and F. H. H. Leenen
Central and peripheral renin-angiotensin systems in ouabain-induced hypertension
Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H624 - H630.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
S. A. Dean, J. Tan, R. White, E. R. O'Brien, and F. H. H. Leenen
Regulation of components of the brain and cardiac renin-angiotensin systems by 17beta-estradiol after myocardial infarction in female rats
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2006; 291(1): R155 - R162.
[Abstract] [Full Text] [PDF]


Home page
J CARDIOVASC PHARMACOL THERHome page
N. S. Dhalla, M. R. Dent, P. S. Tappia, R. Sethi, J. Barta, and R. K. Goyal
Subcellular Remodeling as a Viable Target for the Treatment of Congestive Heart Failure
Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 31 - 45.
[Abstract] [PDF]


Home page
Eur J Heart FailHome page
R.P. Dai, S.T. Dheen, B.P. He, and S.S.W. Tay
Differential expression of cytokines in the rat heart in response to sustained volume overload
Eur J Heart Fail, October 1, 2004; 6(6): 693 - 703.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
X.-L. Tian, Y. M. Pinto, O. Costerousse, W. M. Franz, A. Lippoldt, S. Hoffmann, T. Unger, and M. Paul
Over-expression of angiotensin converting enzyme-1 augments cardiac hypertrophy in transgenic rats
Hum. Mol. Genet., July 15, 2004; 13(14): 1441 - 1450.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X. Wang, E. Sentex, D. Chapman, and N. S. Dhalla
Alterations of adenylyl cyclase and G proteins in aortocaval shunt-induced heart failure
Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H118 - H125.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
T. Mori, Y.-F. Chen, J. A. Feng, T. Hayashi, S. Oparil, and G. J Perry
Volume overload results in exaggerated cardiac hypertrophy in the atrial natriuretic peptide knockout mouse
Cardiovasc Res, March 1, 2004; 61(4): 771 - 779.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
C. J. Zeitz, D. J. Campbell, and J. D. Horowitz
Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans
Hypertension, March 1, 2003; 41(3): 482 - 487.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. L. Segar, G. B. Dalshaug, K. A. Bedell, O. M. Smith, and T. D. Scholz
Angiotensin II in cardiac pressure-overload hypertrophy in fetal sheep
Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R2037 - R2047.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. H. H. Leenen, R. White, and B. Yuan
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system
Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2410 - H2416.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
B. S. Huang, D. Ganten, and F. H. H. Leenen
Responses to Central Na+ and Ouabain Are Attenuated in Transgenic Rats Deficient in Brain Angiotensinogen
Hypertension, February 1, 2001; 37(2): 683 - 686.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
W. C. De Mello and A. H. J. Danser
Angiotensin II and the Heart : On the Intracrine Renin-Angiotensin System
Hypertension, June 1, 2000; 35(6): 1183 - 1188.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
D. E. Dostal and K. M. Baker
The Cardiac Renin-Angiotensin System : Conceptual, or a Regulator of Cardiac Function?
Circ. Res., October 1, 1999; 85(7): 643 - 650.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
C. A.M van Kesteren, J. J Saris, D. H.W Dekkers, J. M.J Lamers, P. R Saxena, M. A.D.H Schalekamp, and A.H.J. Danser
Cultured neonatal rat cardiac myocytes and fibroblasts do not synthesize renin or angiotensinogen: evidence for stretch-induced cardiomyocyte hypertrophy independent of angiotensin II
Cardiovasc Res, July 1, 1999; 43(1): 148 - 156.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
F. H. H. Leenen, V. Skarda, B. Yuan, and R. White
Changes in cardiac ANG II postmyocardial infarction in rats: effects of nephrectomy and ACE inhibitors
Am J Physiol Heart Circ Physiol, January 1, 1999; 276(1): H317 - H325.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
J. P. van Kats, A. H. J. Danser, J. R. van Meegen, L. M. A. Sassen, P. D. Verdouw, and M. A. D. H. Schalekamp
Angiotensin Production by the Heart : A Quantitative Study in Pigs With the Use of Radiolabeled Angiotensin Infusions
Circulation, July 7, 1998; 98(1): 73 - 81.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. Kontogiannis and K. D. Burns
Role of AT1 angiotensin II receptors in renal ischemic injury
Am J Physiol Renal Physiol, January 1, 1998; 274(1): F79 - F90.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Ishigai, T. Mori, T. Ikeda, A. Fukuzawa, and T. Shibano
Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes
Am J Physiol Heart Circ Physiol, December 1, 1997; 273(6): H2659 - H2663.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
F. G. Spinale, M. de Gasparo, S. Whitebread, L. Hebbar, M. J. Clair, D. M. Melton, R. S. Krombach, R. Mukherjee, J. P. Iannini, and S.-J. O
Modulation of the Renin-Angiotensin Pathway Through Enzyme Inhibition and Specific Receptor Blockade in Pacing-Induced Heart Failure : I. Effects on Left Ventricular Performance and Neurohormonal Systems
Circulation, October 7, 1997; 96(7): 2385 - 2396.
[Abstract] [Full Text]


Home page
HypertensionHome page
J. Diez, A. Panizo, M. Hernandez, and J. Pardo
Is the Regulation of Apoptosis Altered in Smooth Muscle Cells of Adult Spontaneously Hypertensive Rats?
Hypertension, March 1, 1997; 29(3): 776 - 780.
[Abstract] [Full Text]